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Background
Tuberculosis is epidemic among workers in South African gold mines. We evaluated 
an intervention to interrupt tuberculosis transmission by means of mass screening 
that was linked to treatment for active disease or latent infection.
Methods
In a cluster-randomized study, we designated 15 clusters with 78,744 miners as either 
intervention clusters (40,981 miners in 8 clusters) or control clusters (37,763 miners in 
7 clusters). In the intervention clusters, all miners were offered tuberculosis screening. 
If active tuberculosis was diagnosed, they were referred for treatment; if not, they were 
offered 9 months of isoniazid preventive therapy. The primary outcome was the 
cluster-level incidence of tuberculosis during the 12 months after the intervention 
ended. Secondary outcomes included tuberculosis prevalence at study completion.
Results
In the intervention clusters, 27,126 miners (66.2%) underwent screening. Of these 
miners, 23,659 (87.2%) started taking isoniazid, and isoniazid was dispensed for 
6 months or more to 35 to 79% of miners, depending on the cluster. The intervention 
did not reduce the incidence of tuberculosis, with rates of 3.02 per 100 person-years 
in the intervention clusters and 2.95 per 100 person-years in the control clusters (rate 
ratio in the intervention clusters, 1.00; 95% confidence interval [CI], 0.75 to 1.34; 
P = 0.98; adjusted rate ratio, 0.96; 95% CI, 0.76 to 1.21; P = 0.71), or the prevalence of 
tuberculosis (2.35% vs. 2.14%; adjusted prevalence ratio, 0.98; 95% CI, 0.65 to 1.48; 
P = 0.90). Analysis of the direct effect of isoniazid in 10,909 miners showed a re-
duced incidence of tuberculosis during treatment (1.10 cases per 100 person-years 
among miners receiving isoniazid vs. 2.91 cases per 100 person-years among con-
trols; adjusted rate ratio, 0.42; 95% CI, 0.20 to 0.88; P = 0.03), but there was a sub-
sequent rapid loss of protection.
Conclusions
Mass screening and treatment for latent tuberculosis had no significant effect on 
tuberculosis control in South African gold mines, despite the successful use of 
isoniazid in preventing tuberculosis during treatment. (Funded by the Consortium 
to Respond Effectively to the AIDS TB Epidemic and others; Thibela TB Current 
Controlled Trials number, ISRCTN63327174.)
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T uberculosis is a leading cause of death in adults globally and was respon-sible for an estimated 1.4 million deaths in 
2011.1,2 Human immunodeficiency virus (HIV) in-
fection, exposure to silica dust in ultradeep mines, 
and close working and living conditions predis-
pose South African gold miners to tuberculosis.3 
Despite standard control measures and annual 
active case finding, the escalating prevalence of 
HIV (29% in 2001) intensified the tuberculosis 
epidemic. Case notifications exceeded 4000 per 
100,000 miners in 19994-6 and remained high in 
2008 (3000 per 100,000 miners), despite the pro-
motion of HIV testing linked to free antiretroviral 
therapy (which substantially reduces the incidence 
of tuberculosis) and targeted isoniazid preventive 
therapy for miners living with HIV.6,7
In a trial in the 1960s in which households 
were randomized in Alaska, where tuberculosis 
was epidemic, isoniazid preventive therapy that 
was delivered to all household members resulted 
in a 55% decline in tuberculosis incidence over 
6 years.8-10 These findings led us to consider a 
novel intervention for gold miners. We reasoned 
that a community-wide intervention, which con-
sisted of screening an entire workforce for active 
tuberculosis and linking that to treatment for 
those with active disease or a course of isoniazid 
preventive therapy for those without active dis-
ease, would reduce the burden of tuberculosis. 
Benefits would accrue both through the indirect 
effect of mass case finding and treatment (thus 
reducing transmission) and through the direct 
protective effect of isoniazid treatment for min-
ers with latent infection. We evaluated this inter-
vention in the Thibela TB study.
Me thods
Study Population
The Thibela TB study was a cluster-randomized 
trial conducted at three gold-mining companies 
in South Africa.11 We included all geographically 
discrete mines (to minimize between-cluster 
mixing) that were expected to be in operation for 
at least 10 years and that had a workforce of at 
least 1000 miners. Clusters comprised all miners 
(both permanent employees and temporary con-
tract workers) at participating mines and associ-
ated hostels, where most miners lived. (For defi-
nitions of types of workers, as well as other 
terms used in the study, see Section S1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.)
Randomization
Clusters were stratified into two groups accord-
ing to rates of tuberculosis case notification (low 
or high) in 2005 (before the study was initiated). 
Randomization was restricted to ensure an over-
all balance according to mining company, prov-
ince, and workforce size.11
Intervention
The entire workforce at each intervention clus-
ter was encouraged to participate in the inter-
vention.11,12 Consenting miners were screened 
for tuberculosis on the basis of symptoms (cough 
with duration >2 weeks, unintentional weight loss, 
or night sweats) and chest radiography for all 
participants.5,13 Miners with symptoms or abnor-
malities on chest radiography suggestive of tu-
berculosis had one sputum specimen collected for 
fluorescence microscopy, mycobacterial culture on 
liquid media, and (if positive) speciation and drug 
sensitivity testing.14 Miners without active tuber-
culosis and no contraindications were offered a 
9-month course of isoniazid (300 mg daily) with 
pyridoxine (25 mg daily), which was dispensed 
monthly by research staff who screened the 
miners for symptoms of tuberculosis or adverse 
effects.11,15 The intervention thus included case 
finding for active tuberculosis at monthly dis-
pensing visits. Tuberculin skin tests were not 
performed, since there was an estimated pre-
trial prevalence of latent tuberculosis infection 
of 89% among the miners.16
Participants who reported symptoms sugges-
tive of hepatotoxicity discontinued isoniazid and 
were referred to mine health services for further 
assessment. Study nurses managed other possi-
ble adverse reactions using clinical algorithms 
and made referrals for treatment if necessary. 
Full details of the study design are provided in 
the study protocol (available at NEJM.org).
Standard of Care
In all clusters, mine health services provided 
comprehensive free medical care. This included 
tuberculosis diagnostic and treatment services, 
HIV testing, and antiretroviral therapy (Section 
S2 in the Supplementary Appendix).
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Study Activities and Timelines
In the baseline survey, we determined the demo-
graphic characteristics, tuberculosis history, and 
risk factors in a random sample of approximately 
1000 miners per cluster by means of interviews 
and standardized reading of a previous occupa-
tional health chest radiograph.11 In intervention 
clusters, miners were recruited during the inter-
vention enrollment period, with the duration of 
the enrollment period varying according to clus-
ter size and continuing until all miners had the 
opportunity to enroll. The subsequent 9-month 
intervention follow-up period allowed all partici-
pants to complete 9 months of isoniazid therapy; 
miners who joined intervention workforces during 
this period were offered enrollment. Corresponding 
periods were defined for control clusters (Fig. 1).
After the intervention follow-up period, we 
measured the incidence of tuberculosis in all 
clusters during the 12-month measurement pe-
riod for the primary outcome. At the end of the 
study, we measured the prevalence of tuberculosis 
among a consecutive sample of employees under-
going their annual medical examination. The man-
agement of suspected tuberculosis is described in 
Section S3 in the Supplementary Appendix.
Study Outcomes
The primary outcome was the incidence of tuber-
culosis (in both pulmonary and extrapulmonary 
forms) during the measurement period for the 
primary outcome. Cases were ascertained primar-
ily from mine health service records of tuberculo-
sis treatment, supplemented by autopsy records to 
ascertain tuberculosis cases that were only identi-
fied post mortem (Section S1 in the Supplemen-
tary Appendix).
Secondary outcomes included the prevalence 
of sputum culture–positive tuberculosis among a 
consecutive sample of employees (in order to avoid 
potential bias due to differential case ascertain-
ment); death from any cause, as ascertained from 
human resource records (with a sensitivity anal-
ysis that included death and “medical boarding” 
[i.e., termination of employment due to ill health]); 
and rates of tuberculosis case notification (all 
treated cases reported by the mine health ser-
vices). The last two outcomes were analyzed over 
the entire study follow-up period. We measured 
adherence to isoniazid treatment on the basis of 
monthly attendance at drug-dispensing visits, 
pill count, and urine testing for isoniazid in a 
random sample of participants (Section S4 in the 
Supplementary Appendix). We also collected data 
on factors that could have an influence on the 
Control Clusters
Intervention Clusters
1.
1.
IPT period
Following
IPT period
2.
Nominal
IPT period
Following
nominal
IPT period
2.
Tuberculosis Episodes: Data Collection
Baseline
survey
Baseline
survey
Intervention
enrollment
3–16 mo
Intervention
follow-up
9 mo
Primary outcome
measurement
12 mo
Primary outcome
measurement
12 mo
Nominal follow-up time
Final
prevalence
survey
Final
prevalence
survey
Figure 1. Study Activities and Timelines.
Shown are the study activities for intervention clusters and control clusters 
(labeled section 1) and horizontal lines illustrating the person-time of follow-up 
for isoniazid preventive therapy (IPT) in the analysis of the direct effect of 
isoniazid (labeled section 2). In all clusters, the baseline survey was con-
ducted at the time of cluster enrollment, and the final prevalence survey 
was conducted at the end of the measurement period for the primary out-
come. Incident cases of tuberculosis were ascertained during the interval 
 between these surveys. After the baseline survey, in the intervention clusters, 
there was an enrollment period, after which there was a 9-month follow-up 
period to allow every participant to complete the 9-month course of IPT, with 
equivalent periods in the control clusters. There was then a 12-month period 
during which the primary outcome of tuber culosis incidence was measured in 
the intervention and control clusters. In section 2 of each part of the figure, 
the horizontal lines represent follow-up time for a sample of participants who 
were included in the cohorts contributing to the analysis of the direct effect of 
the intervention (see the Methods section for inclusion criteria). The time at 
risk was measured from the date that isoniazid was first dispensed (in the 
isoniazid cohort) or from the date of the baseline survey (in the control co-
hort) to the date that tuberculosis treatment was initiated, the date that the 
participant died or left the workforce, or the end of the measurement period 
for the primary outcome, whichever came first. The dotted lines represent the 
first 9-month follow-up period for these participants, and the solid lines rep-
resent the subsequent time periods.
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effectiveness of the intervention (Section S5 in 
the Supplementary Appendix).
Overall Effect of the Intervention
We conducted cluster-level analyses to assess the 
overall effect of the intervention (encompassing 
both direct and indirect effects of the interven-
tion and reflecting coverage achieved)17 with re-
spect to the primary and secondary outcomes, as 
appropriate for a cluster-randomized trial with 
stratified design and a small number of clus-
ters.17 Although the intervention was offered to 
all miners, the analyses of the incidence and 
prevalence of tuberculosis and mortality were re-
stricted to permanent employees, since the ascer-
tainment of outcomes among contract workers, 
who accessed health care outside the mine, was 
incomplete. The analysis of the primary outcome 
was based on all employees in the workforce dur-
ing the enrollment period (or the equivalent for 
control clusters) and at the start of the measure-
ment period for the primary outcome. Person-time 
at risk was measured from the start of the mea-
surement period for the primary outcome to the 
date on which tuberculosis treatment was initi-
ated, the miner died, the miner left the work-
force, or the end of the measurement period for 
the primary outcome — whichever came first. 
The rate of death from any cause was measured 
from the time of cluster enrollment to the end of 
the measurement period for the primary out-
come. Tuberculosis case notifications were ex-
pressed as annualized rates. (Additional statisti-
cal methods are described in Section S6 in the 
Supplementary Appendix.)
Direct Effect of the Intervention
In a post hoc analysis estimating the direct pro-
tective effect of isoniazid, we analyzed two co-
horts comprising all employees who were in-
cluded in the baseline survey, excluding those who 
were receiving tuberculosis treatment or isoniazid 
preventive therapy at the time of the baseline sur-
vey; the isoniazid cohort included employees to 
whom isoniazid preventive therapy was dis-
pensed at least once in intervention clusters as 
part of this study, and the control cohort included 
those who were in control clusters (Fig. 1). The 
time at risk was measured from the date that iso-
niazid was first dispensed in the isoniazid cohort 
or from the date of the baseline survey in the 
control cohort to the date on which tuberculosis 
treatment was initiated, the employee died, the 
employee left the workforce, or the end of the 
measurement period for the primary outcome 
— whichever came first.
We compared the incidence of tuberculosis 
between the isoniazid cohort and the control co-
hort, stratified into three periods: the first 9-month 
period, reflecting the duration of the intended 
administration of isoniazid preventive therapy; 
and two subsequent periods (>9 to 18 months and 
≥18 months), assessing the durability of effect. 
Adjusted and sensitivity analyses were conducted 
(Section S7 in the Supplementary Appendix).
Study Oversight
The study was approved by the ethics committees 
at the University of KwaZulu-Natal and the London 
School of Hygiene and Tropical Medicine and by the 
South African Medicines Control Council and the 
South African Safety in Mines Research Advisory 
Committee. Miners who participated in the inter-
vention and prevalence surveys provided written or 
witnessed oral informed consent. The authors de-
signed the study and vouch for the completeness 
and accuracy of the data presented. The isoniazid 
that was used in the study was donated by Sanofi-
Aventis, which had no other role in the study.
Statistical Analysis
With 15 clusters, we estimated that the study had 
a power of 80% to detect a 40% lower incidence 
of tuberculosis during the measurement period 
for the primary outcome in the intervention clus-
ters than in the control clusters, assuming a co-
efficient of variation of 0.25, a harmonic mean 
workforce size of 2000, and a rate of tuberculosis 
incidence in the control clusters of 2 cases per 
100 person-years. We estimated that the study had 
the same power to detect a 55% lower prevalence of 
tuberculosis in the intervention clusters at the end 
of the study, assuming 1.5% prevalence in control 
clusters and a coefficient of variation of 0.3, with 
a harmonic mean of 750 employees per cluster.11
R esult s
Study Population
Fifteen clusters underwent randomization: eight 
clusters to the intervention and seven to control 
(Fig. 2). Among 78,744 miners (40,981 in the in-
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tervention clusters and 37,763 in the control clus-
ters), 95.9% were men, and the median age was 
41 years. The median cluster size was 4391 miners 
(range, 2727 to 11,325) in the intervention clus-
ters and 5887 miners (range, 1305 to 10,014) in 
the control clusters.
Among 13,958 miners (7561 in the intervention 
clusters and 6397 in the control clusters) in the 
baseline survey, 2.6% had definite silicosis (Sec-
tion S1 in the Supplementary Appendix). A total 
of 12.5% reported having had previous active tu-
ber culosis, 13.6% reported being HIV-positive, 
2.7% reported receiving previous or current anti-
retroviral therapy, and 0.5% reported receiving 
previous or current isoniazid preventive therapy, 
with similar rates in the two study groups (Table 1). 
Mean rates of tuberculosis case notification in 
the 12 months before cluster enrollment were 
slightly lower in the control clusters than in the 
intervention clusters.
participation in the intervention
In eight intervention clusters, 27,126 miners 
(66.2% [range according to cluster, 54.5 to 97.4]) 
enrolled in the study (Fig. S1 and S2 in the Supple-
mentary Appendix). Of these miners, 3467 (12.8%) 
78,744 Miners were employed in total workforce
(15 clusters)
37,763 Were in
7 control clusters
40,981 Were in
8 intervention clusters
38,670 Were evaluated for
tuberculosis incidence
(primary outcome)
31,194 Were included in primary
analysis
41,871 Were evaluated for
tuberculosis incidence
(primary outcome)
31,980 Were included in primary
analysis
6397 Completed baseline
survey (7 clusters)
8046 Migrated in 7139 Migrated out
7561 Completed baseline
survey (8 clusters)
9566 Migrated in 8676 Migrated out
7225 Were evaluated for tuber-
culosis prevalence
(secondary outcome)
7049 Were included in prevalence
analysis
5423 Were included in restricted
analysis
5809 Were evaluated for tuber-
culosis prevalence 
(secondary outcome)
5557 Were included in prevalence
analysis
4457 Were included in restricted
analysis
Figure 2. Study Population and Analyses of Primary and Secondary Outcomes.
Workforce turnover (migration in and out of the companies) in the intervention and control clusters was calculated 
from monthly payroll records provided throughout the study period. In the analysis of the primary outcome of tuber-
culosis incidence, employees were excluded if they were not in the workforce during the enrollment period (3224 in the 
intervention clusters and 3831 in the control clusters) or if they were contract workers (6667 and 3645, respectively). 
In the analysis of the secondary outcome of tuberculosis prevalence, employees were excluded if they had cultures 
that were contaminated (165 in the intervention clusters and 241 in the control clusters) or if they had incomplete 
laboratory data (11 in each group). A restricted analysis of tuberculosis prevalence excluded 1626 employees in the 
intervention group who were not in the workforce during the intervention enrollment period and 1100 employees in 
the control group who were not in the workforce during the equivalent period in control clusters.
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did not start isoniazid preventive therapy; the 
most common reason was a diagnosis of active 
tuberculosis (in 971 miners) or suspected tuber-
culosis (in 734). Isoniazid preventive therapy was 
initiated by 23,659 miners (87.2% [range accord-
ing to cluster, 81.9 to 92.8]); isoniazid pills were 
dispensed for 6 months or more to 54.5% of 
these miners (range according to cluster, 34.9 to 
79.2) (Fig. S1 in the Supplementary Appendix). 
The mean proportion of miners in intervention 
clusters who were given isoniazid pills each 
month during the first 9 months after cluster en-
rollment was 33.5% (range according to cluster, 
9.8 to 65.4) (Fig. S3 in the Supplementary Appen-
dix). More details about adherence are provided 
in Section S4 in the Supplementary Appendix.
Overall Effect of the Intervention
Among 63,174 employees who were included in the 
primary outcome analysis, there were 1743 cases 
of tuberculosis (887 in the intervention clusters 
and 856 in the control clusters), for an inci-
dence of tuberculosis of 3.02 and 2.95 cases per 
100 person-years, respectively (rate ratio in the 
Table 1. Characteristics of Study Participants Who Completed the Baseline Survey.*
Characteristic
Control Clusters
(N = 6397)
Intervention Clusters
(N = 7561)
Total
(N = 13,958)
number/total number (percent)
Age group
18–29 yr 732/6349 (11.5) 746/7504 (9.9) 1,478/13,853 (10.7)
30–39 yr 1590/6349 (25.0) 1801/7504 (24.0) 3,391/13,853 (24.5)
40–49 yr 2742/6349 (43.2) 3343/7504 (44.5) 6,085/13,853 (43.9)
50–70 yr 1285/6349 (20.2) 1614/7504 (21.5) 2,899/13,853 (20.9)
Male sex 6246/6395 (97.7) 7380/7561 (97.6) 13,626/13,956 (97.6)
Country of birth
South Africa 3532/6396 (55.2) 4272/7561 (56.5) 7,804/13,957 (55.9)
Lesotho 1609/6396 (25.2) 2071/7561 (27.4) 3,680/13,957 (26.4)
Mozambique 823/6396 (12.9) 806/7561 (10.7) 1,629/13,957 (11.7)
Other 432/6396 (6.8) 412/7561 (5.4) 844/13,957 (6.0)
Residence in hostel 3838/6396 (60.0) 4391/7558 (58.1) 8,229/13,954 (59.0)
History of working underground 6249/6397 (97.7) 7379/7560 (97.6) 13,628/13,957 (97.6)
Medical history
Current receipt of tuberculosis 
therapy
119/6396 (1.9) 160/7560 (2.1) 279/13,956 (2.0)
Previous tuberculosis 734/6381 (11.5) 1006/7553 (13.3) 1,740 /13,934 (12.5)
HIV-positive by self-report 301/2325 (12.9) 380/2689 (14.1) 681/5,014 (13.6)
Previous or current use of 
isoniazid preventive 
therapy
37/6395 (0.6) 38/7560 (0.5) 75/13,955 (0.5)
Previous or current use of 
antiretroviral therapy
176/6386 (2.8) 199/7544 (2.6) 375/13,930 (2.7)
Silicosis†
None 5779/6127 (94.3) 6488/6774 (95.8) 12,267/12,901 (95.1)
Possible or probable 166/6127 (2.7) 134/6774 (2.0) 300/12,901 (2.3)
Definite 182/6127 (3.0) 152/6774 (2.2) 334/12,901 (2.6)
* During the 12 months before cluster enrollment, there were 1437 treated tuberculosis cases among 39,175 miners in 
the intervention clusters and 1168 cases among 36,030 miners in the control clusters, for rates of tuberculosis case no-
tification of 3668 and 3242 per 100,000 person-years, respectively.
† Silicosis was graded according to the modified International Labour Organization scale.
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intervention clusters, 1.00; 95% confidence in-
terval [CI], 0.75 to 1.34; P = 0.98) (Table 2, and 
Table S1 in the Supplementary Appendix). After 
adjustment for individual-level variables (sex, age, 
and surface or underground work) and cluster-
level variables (prevalence of silicosis, prevalence 
of receipt of antiretroviral therapy, pretrial rates of 
tuberculosis case notification, and randomization 
stratum), there was no significant between-group 
difference in tuberculosis incidence (adjusted rate 
ratio, 0.96; 95% CI, 0.76 to 1.21; P = 0.71). The re-
sults were similar when the analysis was restricted 
to definite or probable tuberculosis cases (Table 2).
The prevalence of tuberculosis was similar in 
the intervention clusters and the control clusters. 
A total of 166 of 7049 employees (2.35%) in the 
intervention clusters and 119 of 5557 employees 
(2.14%) in the control clusters had sputum cul-
tures that were positive for Mycobacterium tubercu-
losis (prevalence ratio, 1.05; 95% CI, 0.60 to 1.82; 
P = 0.86); there was little change in the prevalence 
ratio after adjustment for potential confounders 
(adjusted prevalence ratio, 0.98; 95% CI, 0.65 to 
1.48; P = 0.90) or when the analysis was restricted 
to employees who were in the workforce during 
the main enrollment period (Table 2). The rates of 
death from any cause and of tuberculosis case 
notification did not differ significantly according 
to study group (Table S2, Fig. S4, and Section S8 
in the Supplementary Appendix). Data on factors 
that could have had an influence on the effec-
tiveness of community-wide isoniazid preventive 
therapy are described in Section S9 in the Sup-
plementary Appendix.
Direct Effect of the Intervention
A total of 4646 employees in the intervention group 
and 6263 in the control group met the inclusion 
criteria for the isoniazid and control cohorts and 
were included in the analysis of the direct effect 
of the intervention. (Fig. S5 in the Supplementary 
Appendix). Baseline characteristics were gener-
Table 2. Overall Effect of Community-wide Isoniazid Preventive Therapy: Tuberculosis Incidence and Prevalence.
Outcome Control Clusters Intervention Clusters Rate Ratio (95% CI)*
Cases Rate Cases Rate Unadjusted P Value Adjusted† P Value
no./no. of 
person-yr
per 100 
 person-yr‡
no./no. of 
person-yr
per 100 
 person-yr‡
Primary outcome: 
tuberculosis 
incidence§
Any 856/29,014 2.95 887/29,352 3.02 1.00  
(0.75–1.34)
0.98 0.96  
(0.76–1.21)
0.71
Definite or probable 656/29,014 2.26 703/29,352 2.40 1.07  
(0.70–1.64)
0.72 1.04  
(0.73–1.48)
 0.80
Prevalence Ratio (95% CI)*
no. of cases/ 
total no. %‡
no. of cases/ 
total no. %‡
Secondary outcome: 
tuberculosis 
prevalence¶
All employees 119/5557 2.14 166/7049 2.35 1.05  
(0.60–1.82)
0.86 0.98  
(0.65–1.48)
0.90
Employees in work-
force at the time of 
cluster enrollment
97/4457 2.18 128/5423 2.36 1.05  
(0.62–1.78)
0.85 1.01  
(0.66–1.55)
0.94
* Comparisons are for the intervention clusters versus the control clusters.
† Rate ratios were adjusted for individual-level variables (sex, age, and surface or underground work) and cluster-level variables (prevalence of sili-
cosis and antiretroviral therapy, rate of tuberculosis case notification during the 12 months before cluster enrollment, and randomization strata).
‡ Rates per 100 person-years and percentages were calculated among all employees regardless of cluster.
§ The analysis of incidence during the 12-month measurement period for the primary outcome was restricted to employees who were in the 
cluster during the intervention enrollment period and the equivalent time for control clusters.
¶ The analysis of prevalence at the end of the study excluded employees with contaminated cultures, incomplete laboratory results, or both.
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ally similar in the two cohorts (Table S3 in the Sup-
plementary Appendix). Over the entire follow-up 
period, the incidence of tuberculosis was 1.91 cases 
per 100 person-years in the isoniazid cohort (with 
175 episodes per 9163 person-years) and 2.77 cases 
per 100 person-years in the control cohort (with 
382 episodes per 13,776 person-years) (adjusted 
rate ratio, 0.82; 95% CI, 0.58 to 1.15; P = 0.23) 
(Table 3). During the first 9-month period, the 
incidence of tuberculosis was 58% lower in the 
isoniazid cohort than in the control cohort (ad-
justed rate ratio, 0.42; 95% CI, 0.20 to 0.88; 
P = 0.03) but subsequently was similar in the two 
cohorts (P = 0.02 for the interaction between the 
cohort and follow-up period). The adjusted rate 
ratios for the isoniazid cohort versus the control 
cohort were 0.93 (95% CI, 0.53 to 1.61; P = 0.93) 
for the period from 9 to 18 months and 0.95 
(95% CI, 0.62 to 1.46; P = 0.95) for the period of 
more than 18 months. Sensitivity analyses are 
provided in Table S4 and Section S10 in the Sup-
plementary Appendix.
Discussion
In gold mines, in which a tuberculosis epidemic 
has been unresponsive to conventional control 
measures, we evaluated a community-level inter-
vention that was specifically targeted at interrupt-
ing the transmission of tuberculosis. After screen-
ing miners for active disease, we aimed to offer 
treatment for either active or latent tuberculosis 
to all members of the community simultaneously. 
In the pre-HIV era, several cluster-randomized 
trials of isoniazid preventive therapy were con-
ducted in Native Alaskan households,10 Greenland 
villages,18 and Tunisian city blocks.19 In these 
studies, there was no attempt to interrupt trans-
mission abruptly by coupling tuberculosis screen-
ing with preventive therapy for all community 
members, and the randomization of clusters ap-
pears to have been primarily for logistic conve-
nience, rather than with a specific intention of 
achieving a mass effect. Our intervention did not 
reduce either the incidence or prevalence of tuber-
culosis or the rate of death from any cause, find-
ings that contrasted with the apparent success of 
the intervention in Alaska (but not in either 
Greenland or Tunisia, where the lack of success 
was attributed to an inadequate dose of isoniazid) 
(Section S11 in the Supplementary Appendix).8,20
We can use available data to address some of 
the possible reasons for the lack of effect in our 
study. For isoniazid preventive therapy to have a 
population-level effect on tuberculosis rates, it 
must have a direct effect. Among employees who 
started isoniazid preventive therapy, the inci-
dence of tuberculosis was reduced by 58% dur-
ing the 9-month treatment period, in keeping 
with a very high prevalence of latent tuberculosis 
Table 3. Direct Effect of Isoniazid Preventive Therapy as Shown by Tuberculosis Incidence, According to the Time Interval after Enrollment.*
Time Interval Control Cohort (N = 6263) Isoniazid Cohort (N = 4646) Rate Ratio (95% CI)
Cases Rate† Cases Rate† Unadjusted P Value Adjusted‡ P Value§
no./no. of  
person-yr
per 100  
person-yr
no./no. of  
person-yr
per 100  
person-yr
Overall 382/13,776 2.77 175/9163 1.91 0.77 (0.52–1.15) 0.18 0.82 (0.58–1.15) 0.23
0–9 mo¶ 133/4,564 2.91 37/3358 1.10 0.38 (0.19–0.75)  0.01 0.42 (0.20–0.88)  0.03
>9–18 mo 115/4,243 2.71 74/3156 2.34 0.97 (0.57–1.65) 0.89 0.93 (0.53–1.61) 0.93
>18 mo 134/4,970 2.70 64/2649 2.42 0.83 (0.54–1.27) 0.35 0.95 (0.62–1.46) 0.95
* The direct effect of the intervention was estimated by comparing the incidence of tuberculosis in the isoniazid cohort with that in the con-
trol cohort. Each cohort included all employees who participated in the baseline survey, excluding those receiving tuberculosis treatment or 
isoniazid preventive therapy at the time of the baseline survey. The isoniazid cohort consisted of employees in the intervention clusters to 
whom isoniazid preventive therapy was dispensed at least once as part of the study. The control cohort consisted of employees in the control 
clusters. Incidence was measured from the time of enrollment, which was defined as the date when isoniazid preventive therapy was first 
dispensed (in the isoniazid cohort) or employees participated in the baseline survey (in the control cohort), to the end of the measurement 
period for the primary outcome.
† Rates per 100 person-years were calculated among all employees regardless of cluster.
‡ Rate ratios were adjusted for sex, age, previous tuberculosis, antiretroviral therapy, silicosis on chest radiography, country of origin, residence, 
and randomization stratum.
§ P = 0.02 for the interaction between study cohort and time interval.
¶ Isoniazid preventive therapy was dispensed during the first 9 months of the study.
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infection and protection against disease due to 
recent infection. The effect was lost immediately 
after treatment was discontinued, consistent 
with findings regarding the limited durability of 
isoniazid preventive therapy among HIV-infected 
adults in sub-Saharan Africa.21-25
To interrupt tuberculosis transmission, we 
needed to rapidly find and treat all cases of in-
fectious tuberculosis and achieve high retention 
of miners receiving isoniazid preventive therapy 
in order to prevent reactivation. Participation in 
the intervention and retention in the study were 
variable across clusters. In our best-performing 
cluster with excellent participation and retention, 
the modest effect on case notifications was not 
durable (Fig. S3 in the Supplementary Appendix). 
In other mines, intervention enrollment took 
longer, and retention was lower than desirable. 
Thus, the proportion of miners taking isoniazid 
simultaneously was suboptimal. The effectiveness 
of community-wide isoniazid preventive thera-
py may have been compromised through post-
treatment reinfection — within or outside the 
mines — in miners who had taken isoniazid. 
Transmission in the mines is probably more 
important, since 60% of miners lived in hostels 
and mixed predominantly with miners from the 
same mine. The duration of infectiousness, and 
thus the risk of transmission, could be reduced 
by minimizing the time from diagnosis to the 
initiation of tuberculosis treatment; potential 
ways to achieve this could include the use of 
more sensitive tools for routine annual screen-
ing, such as the automated Xpert MTB/RIF assay 
(which tests for the presence of M. tuberculosis 
[MTB] and resistance to rifampin [RIF]).
We can speculate about the role of other fac-
tors that may have compromised the interven-
tion, although our data with respect to these 
factors are limited. The rapid waning of indi-
vidual protection may have been due to reactiva-
tion of inadequately treated latent tuberculosis 
infection or reinfection caused by high rates of 
ongoing transmission. Gold miners in South 
Africa have a high prevalence of HIV and silico-
sis, both of which are strong risk factors for 
tuberculosis, particularly if the conditions are 
combined.3 Although antiretroviral therapy re-
duces the individual risk of tuberculosis, the 
population-level effect depends on treatment 
coverage, which is determined by eligibility cri-
teria, uptake, retention, and adherence.26,27 Initi-
ating antiretroviral therapy early and maximizing 
coverage may further reduce population-level 
vulnerability to HIV-associated tuberculosis. In-
tensification of dust control to minimize silico-
sis is critical but unlikely to have a short-term 
effect on rates of tuberculosis case notification.
Our study has several limitations. First, we were 
unable to determine the prevalence of HIV, which 
compromised our ability to adjust for HIV effects. 
Second, the relatively small numbers of clusters 
limited the study power; however, the consistent 
lack of effect across various outcomes (tuberculo-
sis incidence and prevalence, mortality, and trends 
in case-notification rates) strongly suggests that 
the observed lack of population-level effect was not 
due to chance. Third, routine tuberculosis-control 
programs differed according to the mining com-
pany (e.g., in the frequency of active case finding); 
however, the intervention and control clusters 
were balanced according to company to minimize 
bias. Finally, there were limitations with respect to 
the analysis of direct effect, which are described 
in Section S12 in the Supplementary Appendix.
In conclusion, we found that a 9-month course 
of community-wide isoniazid preventive therapy 
did not improve tuberculosis control in South 
African gold mines. The best achievable imple-
mentation of the intervention is unlikely to have 
substantially changed the result, given that the 
best-performing cluster had excellent uptake and 
retention, but the intervention nevertheless had a 
modest and short-lived effect. Contributing fac-
tors include increased vulnerability to tuberculo-
sis due to HIV infection and silicosis, along with 
the ongoing transmission of tuberculosis. Tuber-
culosis infection control and strategies for con-
trolling HIV and exposure to silica dust should be 
expanded. Systems that minimize the time from 
a positive microbiologic result to tuberculosis 
treatment are needed. Continuous isoniazid pre-
ventive therapy should be considered for persons 
at highest risk for tuberculosis (i.e., those with 
HIV infection or silicosis) along with strategies to 
maximize retention.21,28-30 Mathematical model-
ing may help identify combinations of strategies 
that are more likely to control tuberculosis in 
gold mines.
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